Biotechnology

OrganaBio's strategic acquisition of Excellos creates a coast-to-coast manufacturing entity, aiming to de-risk and accelerate the complex cell therapy supply chain.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

ICON plc opens a state-of-the-art San Antonio research unit, aiming to accelerate drug development and improve the patient trial experience.

Benchling launches Model Hub, an integrated platform to democratize AI in biotech, aiming to slash R&D timelines by embedding models into daily workflows.

With a new strategic investor and a star executive on its board, Apreo Health is poised to advance its breakthrough BREATHE Airway Scaffold for severe emphysema.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

From malaria vaccines to maglev trains, 12 finalists are celebrated for breakthroughs tackling the world's most pressing environmental and health crises.

A new alliance aims to develop first-in-class drugs for Alzheimer's and Parkinson's by targeting chronic brain inflammation, a key driver of disease.

A new study reveals Efsubaglutide Alfa not only controls diabetes but may also improve the body's own insulin-producing cells, heralding a new era.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

A Boston-area biotech is tackling a key bottleneck in drug manufacturing, promising to unlock a new generation of RNA therapeutics with its novel platform.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

From lab breakthroughs to Hollywood advocacy, the 2026 Reeve Summit showcases a powerful, multi-front strategy to cure paralysis and enrich lives today.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.